Delhi Patent Office has turned down patent applications submitted by GlaxoSmithKline (for its anti-diabetic drug Avandia) and by Pfizer (for its cholesterol-lowering drug Caduet) that, if granted, would have ensured no other company could produce the drugs within the next two decades without the patent-holders’ consent. The applications failed to meet the criterion of being new as well as being more useful than existing compounds. The application for Avandia (rosiglitazone) was refused because it failed to show any “enhanced efficacy over the existing compound”, while that for Caduet was rejected due to the lack of an “inventive step”.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
